CUTISS

CUTISS
CUTISS
CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.
Zürich
Beauty, cosmetics, health care
2017
cutiss.swiss/

Articles about CUTISS:

💡 You’re a corporate or investor and looking for startups that are innovating in the same market as CUTISS? We’re happy to assist you with our Startup Sourcing service.